1 Report Overview |
1.1 Study Scope |
1.2 Key Market Segments |
1.3 Players Covered: Ranking by Cancer Biologics Revenue |
1.4 Market Analysis by Type |
| 1.4.1 Global Cancer Biologiarket Size Growth Rate by Type: 2020 VS 2026 |
| 1.4.2 Monoclonal Antibodies |
| 1.4.3 Vaccines |
| 1.4.4 Cell and Gene Therapy |
| 1.4.5 Others |
1.5 Market by Application |
| 1.5.1 Global Cancer Biologiarket Share by Application: 2020 VS 2026 |
| 1.5.2 Hospitals |
| 1.5.3 Clinics |
| 1.5.4 Others |
1.6 Study Objectives |
1.7 Years Considered |
2 Global Growth Trends by Regions |
2.1 Cancer Biologiarket Perspective (2015-2026) |
2.2 Cancer Biologics Growth Trends by Regions |
| 2.2.1 Cancer Biologiarket Size by Regions: 2015 VS 2020 VS 2026 |
| 2.2.2 Cancer Biologics Historic Market Share by Regions (2015-2020) |
| 2.2.3 Cancer Biologics Forecasted Market Size by Regions (2021-2026) |
2.3 Industry Trends and Growth Strategy |
| 2.3.1 Market Top Trends |
| 2.3.2 Market Drivers |
| 2.3.3 Market Challenges |
| 2.3.4 Porter's Five Forces Analysis |
| 2.3.5 Cancer Biologiarket Growth Strategy |
| 2.3.6 Primary Interviews with Key Cancer Biologics Players (Opinion Leaders) |
3 Competition Landscape by Key Players |
3.1 Global Top Cancer Biologics Players by Market Size |
| 3.1.1 Global Top Cancer Biologics Players by Revenue (2015-2020) |
| 3.1.2 Global Cancer Biologics Revenue Market Share by Players (2015-2020) |
| 轉自：http://www.qdlaimaiche.com/1/27/Global-Cancer-Biologics-Market-Size-Status-and-Forecast-2020-2026.html |
| 3.1.3 Global Cancer Biologiarket Share by Company Type (Tier 1, Tier 2 and Tier 3) |
3.2 Global Cancer Biologiarket Concentration Ratio |
| 3.2.1 Global Cancer Biologiarket Concentration Ratio (CR5 and HHI) |
| 3.2.2 Global Top 10 and Top 5 Companies by Cancer Biologics Revenue in 2019 |
3.3 Cancer Biologics Key Players Head office and Area Served |
3.4 Key Players Cancer Biologics Product Solution and Service |
3.5 Date of Enter into Cancer Biologiarket |
3.6 Mergers & Acquisitions, Expansion Plans |
4 Breakdown Data by Type (2015-2026) |
4.1 Global Cancer Biologics Historic Market Size by Type (2015-2020) |
4.2 Global Cancer Biologics Forecasted Market Size by Type (2021-2026) |
5 Cancer Biologics Breakdown Data by Application (2015-2026) |
5.1 Global Cancer Biologiarket Size by Application (2015-2020) |
5.2 Global Cancer Biologics Forecasted Market Size by Application (2021-2026) |
6 North America |
6.1 North America Cancer Biologiarket Size (2015-2020) |
6.2 Cancer Biologics Key Players in North America (2019-2020) |
6.3 North America Cancer Biologiarket Size by Type (2015-2020) |
6.4 North America Cancer Biologiarket Size by Application (2015-2020) |
7 Europe |
7.1 Europe Cancer Biologiarket Size (2015-2020) |
7.2 Cancer Biologics Key Players in Europe (2019-2020) |
7.3 Europe Cancer Biologiarket Size by Type (2015-2020) |
7.4 Europe Cancer Biologiarket Size by Application (2015-2020) |
8 China |
8.1 China Cancer Biologiarket Size (2015-2020) |
8.2 Cancer Biologics Key Players in China (2019-2020) |
8.3 China Cancer Biologiarket Size by Type (2015-2020) |
8.4 China Cancer Biologiarket Size by Application (2015-2020) |
9 Japan |
9.1 Japan Cancer Biologiarket Size (2015-2020) |
9.2 Cancer Biologics Key Players in Japan (2019-2020) |
9.3 Japan Cancer Biologiarket Size by Type (2015-2020) |
9.4 Japan Cancer Biologiarket Size by Application (2015-2020) |
10 Southeast Asia |
10.1 Southeast Asia Cancer Biologiarket Size (2015-2020) |
10.2 Cancer Biologics Key Players in Southeast Asia (2019-2020) |
10.3 Southeast Asia Cancer Biologiarket Size by Type (2015-2020) |
10.4 Southeast Asia Cancer Biologiarket Size by Application (2015-2020) |
11 India |
11.1 India Cancer Biologiarket Size (2015-2020) |
11.2 Cancer Biologics Key Players in India (2019-2020) |
11.3 India Cancer Biologiarket Size by Type (2015-2020) |
11.4 India Cancer Biologiarket Size by Application (2015-2020) |
12 Central & South America |
12.1 Central & South America Cancer Biologiarket Size (2015-2020) |
12.2 Cancer Biologics Key Players in Central & South America (2019-2020) |
12.3 Central & South America Cancer Biologiarket Size by Type (2015-2020) |
12.4 Central & South America Cancer Biologiarket Size by Application (2015-2020) |
13 Key Players Profiles |
13.1 Company 1 |
| 13.1.1 Company 1 Company Details |
| 13.1.2 Company 1 Business Overview and Its Total Revenue |
| 13.1.3 Company 1 Cancer Biologics Introduction |
| 13.1.4 Company 1 Revenue in Cancer Biologics Business (2015-2020)) |
| 13.1.5 Company 1 Recent Development |
13.2 Company 2 |
| 13.2.1 Company 2 Company Details |
| 13.2.2 Company 2 Business Overview and Its Total Revenue |
| 13.2.3 Company 2 Cancer Biologics Introduction |
| 13.2.4 Company 2 Revenue in Cancer Biologics Business (2015-2020) |
| 13.2.5 Company 2 Recent Development |
13.3 Company 3 |
| 13.3.1 Company 3 Company Details |
| 13.3.2 Company 3 Business Overview and Its Total Revenue |
| 13.3.3 Company 3 Cancer Biologics Introduction |
| 13.3.4 Company 3 Revenue in Cancer Biologics Business (2015-2020) |
| 13.3.5 Company 3 Recent Development |
| 全球抗癌生物制劑市場規模，現狀與預測2020年至2026年 |
13.4 Company 4 |
| 13.4.1 Company 4 Company Details |
| 13.4.2 Company 4 Business Overview and Its Total Revenue |
| 13.4.3 Company 4 Cancer Biologics Introduction |
| 13.4.4 Company 4 Revenue in Cancer Biologics Business (2015-2020) |
| 13.4.5 Company 4 Recent Development |
13.5 Company 5 |
| 13.5.1 Company 5 Company Details |
| 13.5.2 Company 5 Business Overview and Its Total Revenue |
| 13.5.3 Company 5 Cancer Biologics Introduction |
| 13.5.4 Company 5 Revenue in Cancer Biologics Business (2015-2020) |
| 13.5.5 Company 5 Recent Development |
13.6 Company 6 |
| 13.6.1 Company 6 Company Details |
| 13.6.2 Company 6 Business Overview and Its Total Revenue |
| 13.6.3 Company 6 Cancer Biologics Introduction |
| 13.6.4 Company 6 Revenue in Cancer Biologics Business (2015-2020) |
| 13.6.5 Company 6 Recent Development |
13.7 Company 7 |
| 13.7.1 Company 7 Company Details |
| 13.7.2 Company 7 Business Overview and Its Total Revenue |
| 13.7.3 Company 7 Cancer Biologics Introduction |
| 13.7.4 Company 7 Revenue in Cancer Biologics Business (2015-2020) |
| 13.7.5 Company 7 Recent Development |
13.8 Company 8 |
| 13.8.1 Company 8 Company Details |
| 13.8.2 Company 8 Business Overview and Its Total Revenue |
| 13.8.3 Company 8 Cancer Biologics Introduction |
| 13.8.4 Company 8 Revenue in Cancer Biologics Business (2015-2020) |
| 13.8.5 Company 8 Recent Development |
13.9 Company 9 |
| 13.9.1 Company 9 Company Details |
| 13.9.2 Company 9 Business Overview and Its Total Revenue |
| 13.9.3 Company 9 Cancer Biologics Introduction |
| 13.9.4 Company 9 Revenue in Cancer Biologics Business (2015-2020) |
| 13.9.5 Company 9 Recent Development |
13.10 Company 10 |
| 13.10.1 Company 10 Company Details |
| 13.10.2 Company 10 Business Overview and Its Total Revenue |
| 13.10.3 Company 10 Cancer Biologics Introduction |
| 13.10.4 Company 10 Revenue in Cancer Biologics Business (2015-2020) |
| 13.10.5 Company 10 Recent Development |
13.11 Company 11 |
| 10.11.1 Company 11 Company Details |
| 10.11.2 Company 11 Business Overview and Its Total Revenue |
| 10.11.3 Company 11 Cancer Biologics Introduction |
| 10.11.4 Company 11 Revenue in Cancer Biologics Business (2015-2020) |
| 10.11.5 Company 11 Recent Development |
14 Analyst's Viewpoints/Conclusions |
15 Appendix |
15.1 Research Methodology |
| 15.1.1 Methodology/Research Approach |
| 15.1.2 Data Source |
15.2 Disclaimer |
15.3 Author Details |
| List of Tables |
| Table 1. Cancer Biologics Key Market Segments |
| Table 2. Key Players Covered: Ranking by Cancer Biologics Revenue |
| Table 3. Ranking of Global Top Cancer Biologianufacturers by Revenue (US$ Million) in 2019 |
| Table 4. Global Cancer Biologiarket Size Growth Rate by Type (US$ Million): 2020 VS 2026 |
| Table 5. Key Players of Monoclonal Antibodies |
| Table 6. Key Players of Vaccines |
| Table 7. Key Players of Cell and Gene Therapy |
| Table 8. Key Players of Others |
| Table 9. Global Cancer Biologiarket Size Growth by Application (US$ Million): 2020 VS 2026 |
| Table 10. Global Cancer Biologiarket Size by Regions (US$ Million): 2020 VS 2026 |
| Table 11. Global Cancer Biologiarket Size by Regions (2015-2020) (US$ Million) |
| Table 12. Global Cancer Biologiarket Share by Regions (2015-2020) |
| 全球抗癌生物製劑市場規模，現狀與預測2020年至2026年 |
| Table 13. Global Cancer Biologics Forecasted Market Size by Regions (2021-2026) (US$ Million) |
| Table 14. Global Cancer Biologiarket Share by Regions (2021-2026) |
| Table 15. Market Top Trends |
| Table 16. Key Drivers: Impact Analysis |
| Table 17. Key Challenges |
| Table 18. Cancer Biologiarket Growth Strategy |
| Table 19. Main Points Interviewed from Key Cancer Biologics Players |
| Table 20. Global Cancer Biologics Revenue by Players (2015-2020) (Million US$) |
| Table 21. Global Cancer Biologiarket Share by Players (2015-2020) |
| Table 22. Global Top Cancer Biologics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Biologics as of 2019) |
| Table 23. Global Cancer Biologics by Players Market Concentration Ratio (CR5 and HHI) |
| Table 24. Key Players Headquarters and Area Served |
| Table 25. Key Players Cancer Biologics Product Solution and Service |
| Table 26. Date of Enter into Cancer Biologiarket |
| Table 27. Mergers & Acquisitions, Expansion Plans |
| Table 28. Global Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 29. Global Cancer Biologiarket Size Share by Type (2015-2020) |
| Table 30. Global Cancer Biologics Revenue Market Share by Type (2021-2026) |
| Table 31. Global Cancer Biologiarket Size Share by Application (2015-2020) |
| Table 32. Global Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 33. Global Cancer Biologiarket Size Share by Application (2021-2026) |
| Table 34. North America Key Players Cancer Biologics Revenue (2019-2020) (Million US$) |
| Table 35. North America Key Players Cancer Biologiarket Share (2019-2020) |
| Table 36. North America Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 37. North America Cancer Biologiarket Share by Type (2015-2020) |
| Table 38. North America Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 39. North America Cancer Biologiarket Share by Application (2015-2020) |
| Table 40. Europe Key Players Cancer Biologics Revenue (2019-2020) (Million US$) |
| Table 41. Europe Key Players Cancer Biologiarket Share (2019-2020) |
| Table 42. Europe Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 43. Europe Cancer Biologiarket Share by Type (2015-2020) |
| Table 44. Europe Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 45. Europe Cancer Biologiarket Share by Application (2015-2020) |
| Table 46. China Key Players Cancer Biologics Revenue (2019-2020) (Million US$) |
| Table 47. China Key Players Cancer Biologiarket Share (2019-2020) |
| Table 48. China Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 49. China Cancer Biologiarket Share by Type (2015-2020) |
| Table 50. China Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 51. China Cancer Biologiarket Share by Application (2015-2020) |
| Table 52. Japan Key Players Cancer Biologics Revenue (2019-2020) (Million US$) |
| Table 53. Japan Key Players Cancer Biologiarket Share (2019-2020) |
| Table 54. Japan Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 55. Japan Cancer Biologiarket Share by Type (2015-2020) |
| Table 56. Japan Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 57. Japan Cancer Biologiarket Share by Application (2015-2020) |
| Table 58. Southeast Asia Key Players Cancer Biologics Revenue (2019-2020) (Million US$) |
| Table 59. Southeast Asia Key Players Cancer Biologiarket Share (2019-2020) |
| Table 60. Southeast Asia Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 61. Southeast Asia Cancer Biologiarket Share by Type (2015-2020) |
| Table 62. Southeast Asia Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 63. Southeast Asia Cancer Biologiarket Share by Application (2015-2020) |
| Table 64. India Key Players Cancer Biologics Revenue (2019-2020) (Million US$) |
| Table 65. India Key Players Cancer Biologiarket Share (2019-2020) |
| Table 66. India Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 67. India Cancer Biologiarket Share by Type (2015-2020) |
| Table 68. India Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 69. India Cancer Biologiarket Share by Application (2015-2020) |
| Table 70. Central & South America Key Players Cancer Biologics Revenue (2019-2020) (Million US$) |
| Table 71. Central & South America Key Players Cancer Biologiarket Share (2019-2020) |
| Table 72. Central & South America Cancer Biologiarket Size by Type (2015-2020) (Million US$) |
| Table 73. Central & South America Cancer Biologiarket Share by Type (2015-2020) |
| Table 74. Central & South America Cancer Biologiarket Size by Application (2015-2020) (Million US$) |
| Table 75. Central & South America Cancer Biologiarket Share by Application (2015-2020) |
| Table 76. Company 1 Company Details |
| Table 77. Company 1 Business Overview |
| Table 78. Company 1 Product |
| Table 79. Company 1 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 80. Company 1 Recent Development |
| quánqiú kàng ái shēngwù zhìjì shìchǎng guīmó, xiànzhuàng yǔ yùcè 2020 nián zhì 2026 nián |
| Table 81. Company 2 Company Details |
| Table 82. Company 2 Business Overview |
| Table 83. Company 2 Product |
| Table 84. Company 2 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 85. Company 2 Recent Development |
| Table 86. Company 3 Company Details |
| Table 87. Company 3 Business Overview |
| Table 88. Company 3 Product |
| Table 89. Company 3 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 90. Company 3 Recent Development |
| Table 91. Company 4 Company Details |
| Table 92. Company 4 Business Overview |
| Table 93. Company 4 Product |
| Table 94. Company 4 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 95. Company 4 Recent Development |
| Table 96. Company 5 Company Details |
| Table 97. Company 5 Business Overview |
| Table 98. Company 5 Product |
| Table 99. Company 5 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 100. Company 5 Recent Development |
| Table 101. Company 6 Company Details |
| Table 102. Company 6 Business Overview |
| Table 103. Company 6 Product |
| Table 104. Company 6 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 105. Company 6 Recent Development |
| Table 106. Company 7 Company Details |
| Table 107. Company 7 Business Overview |
| Table 108. Company 7 Product |
| Table 109. Company 7 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 110. Company 7 Recent Development |
| Table 111. Company 8 Business Overview |
| Table 112. Company 8 Product |
| Table 113. Company 8 Company Details |
| Table 114. Company 8 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 115. Company 8 Recent Development |
| Table 116. Company 9 Company Details |
| Table 117. Company 9 Business Overview |
| Table 118. Company 9 Product |
| Table 119. Company 9 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 120. Company 9 Recent Development |
| Table 121. Company 10 Company Details |
| Table 122. Company 10 Business Overview |
| Table 123. Company 10 Product |
| Table 124. Company 10 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 125. Company 10 Recent Development |
| Table 126. Company 11 Company Details |
| Table 127. Company 11 Business Overview |
| Table 128. Company 11 Product |
| Table 129. Company 11 Revenue in Cancer Biologics Business (2015-2020) (Million US$) |
| Table 130. Company 11 Recent Development |
| Table 131. Research Programs/Design for This Report |
| Table 132. Key Data Information from Secondary Sources |
| Table 133. Key Data Information from Primary Sources |
| List of Figures |
| Figure 1. Global Cancer Biologiarket Share by Type: 2020 VS 2026 |
| Figure 2. Monoclonal Antibodies Features |
| Figure 3. Vaccines Features |
| Figure 4. Cell and Gene Therapy Features |
| Figure 5. Others Features |
| Figure 6. Global Cancer Biologiarket Share by Application: 2020 VS 2026 |
| Figure 7. Hospitals Case Studies |
| Figure 8. Clinics Case Studies |
| Figure 9. Others Case Studies |
| Figure 10. Cancer Biologics Report Years Considered |
| Figure 11. Global Cancer Biologiarket Size YoY Growth 2015-2026 (US$ Million) |
| Figure 12. Global Cancer Biologiarket Share by Regions: 2020 VS 2026 |
| Figure 13. Global Cancer Biologiarket Share by Regions (2021-2026) |
| Figure 14. Porter's Five Forces Analysis |
| 世界のがん生物製剤市場規模、ステータスと予測2020年から2026年 |
| Figure 15. Global Cancer Biologiarket Share by Players in 2019 |
| Figure 16. Global Top Cancer Biologics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cancer Biologics as of 2019 |
| Figure 17. The Top 10 and 5 Players Market Share by Cancer Biologics Revenue in 2019 |
| Figure 18. North America Cancer Biologiarket Size YoY Growth (2015-2020) (Million US$) |
| Figure 19. Europe Cancer Biologiarket Size YoY Growth (2015-2020) (Million US$) |
| Figure 20. China Cancer Biologiarket Size YoY Growth (2015-2020) (Million US$) |
| Figure 21. Japan Cancer Biologiarket Size YoY Growth (2015-2020) (Million US$) |
| Figure 22. Southeast Asia Cancer Biologiarket Size YoY Growth (2015-2020) (Million US$) |
| Figure 23. India Cancer Biologiarket Size YoY Growth (2015-2020) (Million US$) |
| Figure 24. Central & South America Cancer Biologiarket Size YoY Growth (2015-2020) (Million US$) |
| Figure 25. Company 1 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 26. Company 1 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 27. Company 2 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 28. Company 2 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 29. Company 3 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 30. Company 3 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 31. Company 4 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 32. Company 4 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 33. Company 5 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 34. Company 5 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 35. Company 6 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 36. Company 6 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 37. Company 7 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 38. Company 7 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 39. Company 8 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 40. Company 8 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 41. Company 9 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 42. Company 9 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 43. Company 10 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 44. Company 10 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 45. Company 11 Total Revenue (US$ Million): 2019 Compared with 2018 |
| Figure 46. Company 11 Revenue Growth Rate in Cancer Biologics Business (2015-2020) |
| Figure 47. Bottom-up and Top-down Approaches for This Report |
| Figure 48. Data Triangulation |
| Figure 49. Key Executives Interviewed |
略……
如需購買《Global Cancer Biologics Industry Research and Trends Forecast Report 2020-2026》，編號：2687271
請您致電：400 612 8668、010-6618 1099、66182099、66183099
或Email至：KF@Cir.cn 【網上訂購】 ┊ 下載《訂購協議》 ┊ 了解“訂購流程”
請您致電：400 612 8668、010-6618 1099、66182099、66183099
或Email至：KF@Cir.cn 【網上訂購】 ┊ 下載《訂購協議》 ┊ 了解“訂購流程”
京公網安備 11010802027365號